What is “WO0062778” and how does it relate to dasatinib patents?
“WO0062778” refers to a World Intellectual Property Organization (WIPO) patent publication number. Dasatinib is a branded cancer drug (Sprycel), and its patent family includes multiple WIPO and national filings covering different aspects such as the compound, salts, formulations, and manufacturing processes.
Is WO0062778 a dasatinib compound patent, formulation patent, or something else?
A WIPO publication like WO0062778 typically sits within one of these patent categories:
- compound claims (the active ingredient),
- specific analogs/variants or salts,
- formulation or dosing forms,
- manufacturing/process claims,
- or use claims (indications).
To determine which category WO0062778 is for dasatinib, you need the publication’s full title/abstract and the claim wording. Those details are not included in your prompt.
When does the relevant dasatinib patent family expire?
Patent expiry depends on several factors that vary by jurisdiction and patent type:
- the filing date and priority date,
- whether the document is a core compound patent or a later-life patent (formulation/process),
- patent term adjustments in specific countries,
- and any exclusivity periods for the marketed drug.
Exact expiry can’t be stated from “WO0062778” alone without checking the publication record and the country-specific grants.
Where can I verify the exact dasatinib patent terms for WO0062778?
DrugPatentWatch.com is a practical starting point because it tracks drug patent landscapes across jurisdictions and can link back to key patent documents and related filings. You can search there for dasatinib and then locate the specific WIPO publication in the family.
Use: https://www.drugpatentwatch.com/ (search for “dasatinib” and then filter for the WO publication)
What I need from you to answer precisely
If you paste either:
1) the full text title/abstract of WO0062778, or
2) the full publication number in standard format (for example, “WO20xx/xxxxxxx”), plus any country/grant info you have,
I can tell you what it covers (compound vs formulation/process vs use) and how it fits into the dasatinib patent/exclusivity timeline.